Proteomics Center, Erasmus University Medical Center, Rotterdam, the Netherlands.
Proteomics Center, Erasmus University Medical Center, Rotterdam, the Netherlands.
J Proteomics. 2022 Jun 30;262:104592. doi: 10.1016/j.jprot.2022.104592. Epub 2022 Apr 27.
The removal of (poly)ubiquitin chains at the proteasome is a key step in the protein degradation pathway that determines which proteins are degraded and ultimately decides cell fate. Three different deubiquitinating enzymes (DUBs) are associated to the human proteasome, PSMD14 (RPN11), USP14 and UCH37 (UCHL5). However, the functional roles and specificities of these proteasomal DUBs remain elusive. To reveal the specificities of proteasome associated DUBs, we used SILAC based quantitative ubiquitinomics to study the effects of CRISPR-Cas9 based knockout of each of these DUBs on the dynamic cellular ubiquitinome. We observed distinct effects on the global ubiquitinome upon removal of either USP14 or UCH37, while the simultaneous removal of both DUBs suggested less functional redundancy than previously anticipated. We also investigated whether the small molecule inhibitor b-AP15 has the potential to specifically target USP14 and UCH37 by comparing treatment of wild-type versus USP14/UCH37 double-knockout cells with this drug. Strikingly, broad and severe off-target effects were observed, questioning the alleged specificity of this inhibitor. In conclusion, this work presents novel insights into the function of proteasome associated DUBs and illustrates the power of in-depth ubiquitinomics for screening the activity of DUBs and of DUB modulating compounds.
Introduction: The removal of (poly)ubiquitin chains at the proteasome is a key step in the protein degradation pathway that determines which proteins are degraded and ultimately decides cell fate. Three different deubiquitinating enzymes (DUBs) are associated to the human proteasome, PSMD14/RPN11, USP14 and UCH37/UCHL5. However, the functional roles and specificities of these proteasomal DUBs remains elusive.
MATERIALS & METHODS: We have applied a SILAC based quantitative ubiquitinomics to study the effects of CRISPR-Cas9 based knockout of each of these DUBs on the dynamic cellular ubiquitinome. Also, we have studied the function of the small molecule inhibitor b-AP15, which has the potential to specifically target USP14 and UCH37.
We report distinct effects on the ubiquitinome and the ability of the proteasome to clear proteins upon removal of either USP14 or UCH37, while the simultaneous removal of both DUBs suggests less redundancy than previously anticipated. In addition, broad and severe off-target effects were observed for b-AP15, questioning the alleged specificity of this inhibitor.
This work presents novel insights into the function of proteasome associated DUBs and illustrates the power of in-depth ubiquitinomics for screening the activity of DUBs and of DUB modulating compounds.
蛋白酶体上(多)泛素链的去除是蛋白降解途径中的一个关键步骤,该途径决定了哪些蛋白质被降解,最终决定了细胞命运。三种不同的去泛素化酶(DUBs)与人类蛋白酶体相关联,即 PSMD14(RPN11)、USP14 和 UCH37(UCHL5)。然而,这些蛋白酶体 DUB 的功能作用和特异性仍然难以捉摸。为了揭示与蛋白酶体相关的 DUB 的特异性,我们使用基于 SILAC 的定量泛素组学来研究基于 CRISPR-Cas9 的每种 DUB 敲除对动态细胞泛素组的影响。我们观察到在去除 USP14 或 UCH37 时,对全局泛素组有明显的影响,而同时去除这两种 DUB 表明功能冗余性低于先前预期。我们还研究了小分子抑制剂 b-AP15 是否有可能通过比较用该药物处理野生型与 USP14/UCH37 双敲除细胞来特异性靶向 USP14 和 UCH37。令人惊讶的是,观察到广泛而严重的脱靶效应,质疑该抑制剂的所谓特异性。总之,这项工作为蛋白酶体相关 DUB 的功能提供了新的见解,并说明了深入的泛素组学在筛选 DUB 活性和 DUB 调节化合物方面的强大功能。
介绍:蛋白酶体上(多)泛素链的去除是蛋白降解途径中的一个关键步骤,该途径决定了哪些蛋白质被降解,最终决定了细胞命运。三种不同的去泛素化酶(DUBs)与人类蛋白酶体相关联,即 PSMD14/RPN11、USP14 和 UCH37/UCHL5。然而,这些蛋白酶体 DUB 的功能作用和特异性仍然难以捉摸。
我们应用基于 SILAC 的定量泛素组学来研究基于 CRISPR-Cas9 的每种 DUB 敲除对动态细胞泛素组的影响。此外,我们还研究了小分子抑制剂 b-AP15 的功能,该抑制剂有可能特异性靶向 USP14 和 UCH37。
我们报告了在去除 USP14 或 UCH37 时,泛素组和蛋白酶体清除蛋白质的能力有明显的影响,而同时去除这两种 DUB 表明冗余性低于先前预期。此外,b-AP15 观察到广泛而严重的脱靶效应,质疑该抑制剂的所谓特异性。
这项工作为蛋白酶体相关 DUB 的功能提供了新的见解,并说明了深入的泛素组学在筛选 DUB 活性和 DUB 调节化合物方面的强大功能。